2010_10_12_14-15-08_Sterling_Memorial_Li

YSBS Sponsors

YSBS programming is made possible by the support of our sponsors. We would like to thank all our corporate sponsors for making our events possible and supporting our student organization as we plan new events in the near future!

Interested in sponsoring YSBS? Contact us at ysbsstudentbusinesssociety@yale.edu and we're happy to build a sponsorship package that works best for you!

2021 YSBS Sapphire Sponsors

ARVN.png

Arvinas

Arvinas is a clinical-stage biopharmaceutical company leading the way in targeted protein degradation therapeutics. Targeted protein degradation is an entirely new approach to drug development – one that could dramatically change the lives of patients who have few or no therapeutic options. Arvinas is the first company to focus solely on protein degradation and its platform technology is the most advanced in the field. Since its founding in 2013, Arvinas’ PROTAC® Discovery Engine has been driving the most significant breakthroughs in the industry. Arvinas’ pipeline encompasses a range of validated and undruggable targets in oncology, immuno-oncology, and neuroscience. This includes two clinical-stage programs: ARV-110, which has demonstrated safety and efficacy in men with late-line metastatic castrate-resistant prostate cancer, and ARV-471, which has the potential to be a best-in-class estrogen receptor-targeting therapy for patients with breast cancer.

 

#TeamArvinas is made up of more than 200 passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and purpose – to improve the well-being of patients and families impacted by the devastating diseases Arvinas is working to treat. It’s an exciting time to be in drug development and it’s an exciting time to be at Arvinas. But don’t just take our word for it – here’s what Arvinas employees are saying. For more information, please visit www.arvinas.com.

Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Our US headquarter is based in Ridgefield, CT.  Founded in 1885 our family-owned company operates in 103 countries, with 145 affiliates and 47,500 employees. We focus on researching, developing, manufacturing and marketing new medications to improve the health and quality of life for both humans and animals.  At Boehringer Ingelheim we are powered by our people. We nurture a diverse, collaborative and open environment. We are driven by results and work with integrity and passion.

Boehringer Ingelheim

1200px-Boehringer_Ingelheim_Logo.svg.png

2021 YSBS Gold Sponsors

10X Genomics

1024px-10x_Genomics_logo.svg.png

ClearView Healthcare Partners

Clearview.png

Finnegan

finnegan.png

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest law firms in the world focusing solely on intellectual property law.  Finnegan practices all aspects of patent, trademark, copyright, and trade secret law including transactions, counseling, prosecution, litigation, licensing, and portfolio management.  We have offices in Atlanta, GA; Boston, MA; London, UK; Palo Alto, CA; Reston, VA; Seoul, South Korea; Shanghai, China; Taipei, Taiwan; Tokyo Japan; and Washington, DC.

 

In keeping with Finnegan’s interest in developing its own talent, Finnegan has a well-established technical specialist program designed for those who have been accepted into or are in the process of applying to law school.  Our technical specialists, many of whom hold Ph.D.s or have several years of industry experience, cover the full spectrum of scientific disciplines from biology and chemistry to engineering and computer science.  They work with clients in a variety of industries including alternative energy, biotechnology, pharmaceuticals, chemical, consumer products, industrial manufacturing, medical devices, electronics, robotics, machine learning, and computers.

Healthcare Consultancy Group (HCG) serves the pharmaceutical, biotech, and device industries by providing strategic, scientific communications solutions at all stages of the product lifecycle.  HCG is comprised of six interconnected agencies with distinct personalities and complementary skills.  All share a common commitment to bringing our clients’ medicines closer to the patients who need them.  Part of Omnicom Healthcare Group, HCG is a global leader in the healthcare segment, with over 650 employees across multiple functions and locations, including a growing remote workforce.  We are a scientifically rigorous, strategically focused, creatively balanced agency built for the future.

Healthcare Consultancy Group

hcg-logo-with-tagline-full-colour-rgb.pn

IsoPlexis

Isoplexis.png

ThermoFisher Scientific

1200px-Thermo_Fisher_Scientific_logo.svg

2021 YSBS Silver Sponsors

Artizan Bioscience

Artizan Biosciences identifies and distinguishes bacteria in the gut that predispose people to disease with the goal of developing new and potentially curative treatments for unmet medical needs. This unique approach is applicable to a variety of microbiota-driven diseases including inflammatory bowel disease (IBD), central nervous system disorders, obesity, metabolic syndrome, and autoimmune disease. Founded to advance the IgA-SEQ™ technology platform of renowned immunologists Richard Flavell, PhD, Noah Palm, PhD, and Marcel R. de Zoete, PhD, Artizan’s lead program focuses on IBD, a group of inflammatory conditions of the small intestine and colon including ulcerative colitis and Crohn’s disease. Artizan Biosciences is located adjacent to Yale University at Science Park in New Haven, CT.

 

Artizan’s vision is to cure and protect people from diseases with a basis in the microbiome.

 

Artizan’s mission is to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies.

AstraZeneca

5847ebf8cef1014c0b5e4859.png

AtlasXomics

Bio-Rad Laboratories

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With a diversified fund and over 200 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 33 years. Canaan’s focus areas include consumer tech, fintech, enterprise/SaaS, frontier tech, biopharma, digital health and medtech.

Canaan will be promoting positions at EvolveImmune at the career fair:

Job openings: https://www.evolveimmune.com/careers

Canaan Partners

Canaan_Logotype_RGB Blue.png

Bio-Rad’s Digital Biology Group is a multidisciplinary team developing products using our Droplet Digital™ technology that are having a large impact in both research and healthcare. Every day, scientists and clinicians around the world use our ddPCR systems to make new discoveries and revolutionize clinical decision-making with break-through liquid biopsy applications. We’re looking for a motivated and skilled Research Associate II, Oncology to join our assay development team.

Dyno Therapeutics

Dyno-Logo-Final-050820-2.png

Dyno Therapeutics is reshaping the gene therapy landscape through AI-powered vectors. Through the application of our transformative technologies and strategic partnerships with leaders in gene therapy, we believe a future with life changing gene therapies for millions of people is within reach. 

Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and machine learning experts. Dyno was named Xconomy’s 2020 Startup of the Year! 

Calico Labs

Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases.

Editas Medicine

Editas_Medicine_logo.png

F-Prime Capital

F-PrimeSig1A.png

F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies.

 

With over two billion dollars under management and a global portfolio of more than 200 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech, and health IT & services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech; while we’re early-stage investors by choice, we’ll back exceptional teams at any stage. Our team of investors, engineers, doctors, and scientists is committed to bringing the insight, domain expertise, and relationships required to help our companies make a transformational impact.

 

F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com ​and follow us on Twitter and LinkedIn.

Halda Therapeutics is a venture-backed biotechnology platform company focused on the discovery of medicines through the creation of innovative molecules that modify disease-causing pathways. Halda was founded in 2019 by Professor Craig Crews (MCDB) and is funded by top-tier venture capital firms. The Company will be moving to new lab space in New Haven, CT in the first half of 2021.

Halda Therapeutics

haldalogo_rgb (1).jpg

Johnson & Johnson

Johnson-Johnson-Logo.png

Teams from Johnson & Johnson’s consumer business are improving quality of life by creating digital tools to help people track the health of their skin. Those working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals are using AI to discover lifesaving drugs and shorten clinical trials. Data science is unlocking ways to solve problems never before thought possible—and we’re looking for people ready use their invaluable technology skills, expertise, and perspectives to change the trajectory of health for humanity.

LEK Consulting

download.png

L.E.K. Consulting is one of the premier strategy consulting firms worldwide. At L.E.K., we are passionate about helping our clients succeed with breakthrough insights that drive real impact. Our clients view us as trusted partners that help address their most pressing challenges and biggest opportunities. 

Our uncompromising approach is grounded in deep industry expertise, rigorous analysis, and a commitment to driving practical results that exceed our clients’ expectations. To do this, we hire the best and the brightest, and offer them an unparalleled experience to rapidly develop their skills. This strategy drives L.E.K.’s robust growth, and gives us the benefits of global scale with a small-firm feel.

Founded in 1983, L.E.K. employs more than 1,400 professionals across five continents, and is consistently recognized as one of the industry’s best firms to work for. For more information, visit lek.com.

Morrison Foerster

06_21_Yello Website_LoginLogo.png

Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of distributors, agents and eight subsidiaries. Learn more at www.neb.com.

New England Biolabs

download (1).png

Nuvera Life Science Consulting

small_logo.png

Nuvera Life Science Consulting is a leader in helping pharma/biotech companies design and implement exceptional patient and healthcare provider treatment experiences for their therapies. For over a decade, our team of Treatment Experience Architects has solved complex problems across a multitude of cutting-edge technologies such as Gene Therapy and CAR/TCR-T as well as more traditional oncology, neuroscience, and other specialty/rare disease areas.

 

We are looking for individuals who are exceptionally versatile athletes when it comes to solving complex problems and communicating impactfully. Your skills are much more important to us than direct industry experience – we can teach you that! Along the way you’ll be helping small, mid, and large pharma/biotech clients improve the lives of their patients and providers, while working in a tight-knit team with an exceptional culture of passion, learning, creativity, fun, and camaraderie.

Co-founded in 2017 by two pioneers in genome editing technology, Dr. Luhan Yang and Dr. George Church, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies. All positions are based in Hangzhou, China.

All job postings are for positions in China.

Qihan Biotech

启函LOGO横版.jpg

Schrodinger

Wiki-logo-schrodinger-2018.png

2021 YSBS Standard Sponsors

ADAM

adam-logo_NEW.png

A.D.A.M. was founded in 2018 by 3D printing company Kwambio and WeFund Ventures in Ukraine. The initial vision of the company was to create a carshop-like infrastructure where any part of the human body can be treated like a replaceable part. A.D.A.M. team decided to start the development of the project with a focus on bone implants and have developed proprietary 3D printing technology and material composites for the implants. The first prototypes passed pre-clinical trials in wistar rats. Successful results of the trials allowed A.D.A.M. to file the Q-Submission to the FDA. In their response, the FDA confirmed A.D.A.M. biopolymer and bioceramic bone implants' 510(k) eligibility. Concurrently, the company moved its HQs to the Technology Incubation Program at University of Connecticut.

FogPharma® is pioneering the discovery, development, and commercialization of Helicon™ peptides, an exciting new drug modality that uniquely combines the cell-permeability of traditional small molecule drugs with the specificity, broad target accessibility and discovery speed of monoclonal antibody drugs. Our patented Helicon peptide technology allows us to modulate the activity of well-known intracellular disease drivers that have thus far evaded small molecule and biologic therapies.

 

FogPharma’s lead program targets beta-catenin, a cancer driver in the WNT pathway. Inhibition of beta catenin has the potential to benefit more than one-fifth of all cancer patients, and is just one of many opportunities that Fog’s lead-discovery platform will change future medicines, therapies and lives.

Fog Pharma

fogPharma_color_logo.png

Clarion Consulting

5ac1e75a-8b8f-43f5-a297-8f980ade6366-152

Clarion is a life sciences strategy and organizational consultancy that works together with its clients to envision, craft, and enable growth through innovation and leadership. Across therapeutic categories, Clarion collaborates deeply with its clients to tackle their most complex cross-functional business challenges and decisions throughout the product and company lifecycle. From start-up to global multinational companies, Clarion helps assemble and deliver on inspired strategies that require creativity, insight, and collaboration. Clarion builds leaders across the industry.

Clarion attracts the brightest and most forward-thinking minds in life sciences. Our model and project mix cultivate life science leaders. Learn more at: https://clarionhealthcare.com/